X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.fiercebiotech.com/biotech/bain-goes-big-again-leading-350m-round-fund-oral-challenger-blockbuster-asthma-biologics
https://www.businesswire.com/news/home/20210114005054/en/Knopp-Biosciences-Announces-Positive-Top-Line-Results-from-the-Phase-2-EXHALE-Trial-of-Oral-Dexpramipexole-in-Moderate-to-Severe-Eosinophilic-Asthma
https://www.globenewswire.com/news-release/2020/09/16/2094345/0/en/Knopp-Biosciences-Completes-Enrollment-in-Phase-2-Trial-of-Oral-Dexpramipexole-in-Eosinophilic-Asthma.html#:~:text=PITTSBURGH%2C%20Sept.%2016%2C%202020,%2Dto%2Dsevere%20eosinophilic%20asthma.&text=The%20primary%20endpoint%20is%20the%20change%20in%20peripheral%20blood%20eosinophil%20count.
https://www.fiercebiotech.com/biotech/biogen-s-antisense-als-drug-checks-boxes-phase-1-2-en-route-to-phase-3-readout
https://www.clinicaltrialsarena.com/news/knopp-dexpramipexole-phase-ii/
https://www.businesswire.com/news/home/20190424005324/en/Knopp-Biosciences-Receives-FDA-Orphan-Drug-Designation/?feedref=JjAwJuNHiystnCoBq_hl-WBlLQO14j4QZPTyX5CYOnwC4VjN53jumZRlnzhBoBxGrCOi9QzgjCezTS3Nw_X6kJUrpSBm-Hav1w-UkdSlG3ltkRSnqzf6ourQGu_UA28CzZCGORvG0LE20YOvo49uqw==
Market Place
Share 
